Literature DB >> 12424231

Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase.

Philip J Moos1, Kornelia Edes, Pamela Cassidy, Edmond Massuda, F A Fitzpatrick.   

Abstract

Tumor suppressor p53 exhibits an enigmatic phenotype in cells exposed to electrophilic, cyclopentenone prostaglandins of the A and J series. Namely, cells harboring a wild-type p53 gene accumulate p53 protein that is conformationally and functionally impaired. This occurs via an unknown molecular mechanism. We report that electrophilic cyclopentenone prostaglandins covalently modify and inhibit thioredoxin reductase, a selenoprotein that governs p53 and other redox-sensitive transcription factors. This mechanism accounts fully for the unusual p53 phenotype in cells exposed to electrophilic prostaglandins. Based on this mechanism we derived, tested, and affirmed several predictions regarding the kinetics of p53 inactivation; the protective effects of selenium; the structure-activity relationships for inhibition of thioredoxin reductase and impairment of p53 by electrophilic lipids; the susceptibility of hypoxia-inducible factor to inactivation by electrophilic lipids; and the equivalence of chemical inactivation of p53 to deletion of a p53 allele. Chemical precepts dictate that other electrophilic agents should also inhibit thioredoxin reductase and impair its governance of redox-sensitive proteins. Our results provide a novel framework to understand how endogenous and exogenous electrophiles might participate in carcinogenesis; how selenoproteins and selenium might confer protection against cancer; how certain tumors might acquire their paradoxical p53 phenotype; and how chronic inflammation might heighten the risk for cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424231     DOI: 10.1074/jbc.M211134200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.

Authors:  Robyn L Poerschke; Philip J Moos
Journal:  Biochem Pharmacol       Date:  2010-10-12       Impact factor: 5.858

Review 2.  The organization and consequences of eicosanoid signaling.

Authors:  Roy J Soberman; Peter Christmas
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 3.  The electrophile responsive proteome: integrating proteomics and lipidomics with cellular function.

Authors:  Ashlee N Higdon; Aimee Landar; Stephen Barnes; Victor M Darley-Usmar
Journal:  Antioxid Redox Signal       Date:  2012-04-18       Impact factor: 8.401

Review 4.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

5.  Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism.

Authors:  Ryuta Tobe; Min-Hyuk Yoo; Noelia Fradejas; Bradley A Carlson; Soledad Calvo; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Biochem J       Date:  2012-08-01       Impact factor: 3.857

Review 6.  Selenoproteins that function in cancer prevention and promotion.

Authors:  Dolph L Hatfield; Min-Hyuk Yoo; Bradley A Carlson; Vadim N Gladyshev
Journal:  Biochim Biophys Acta       Date:  2009-03-09

Review 7.  Signaling actions of electrophiles: anti-inflammatory therapeutic candidates.

Authors:  Alison L Groeger; Bruce A Freeman
Journal:  Mol Interv       Date:  2010-02

Review 8.  Formation and signaling actions of electrophilic lipids.

Authors:  Francisco J Schopfer; Chiara Cipollina; Bruce A Freeman
Journal:  Chem Rev       Date:  2011-09-20       Impact factor: 60.622

9.  JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.

Authors:  Kornelia Edes; Pamela Cassidy; Paul J Shami; Philip J Moos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

10.  Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.

Authors:  J P Lau; K L Weatherdon; V Skalski; D W Hedley
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.